This complexity of the role of EGF signaling pathway in ovarian cancer explained, at least in part, why several clinical trials performed on patients with positive EGFR or HER2 immunostaining or genetic changes did not show satisfying response to HER-targeted therapy [23–25]. The gene discussed is ERBB2; the disease is ovarian carcinoma.